FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Experimental Pancreatic Cancer Drug Gets Fast Track

[ Price : $8.95]

FDA grants the Experimental Drug Development Center a fast-track designation for EBC-129 and its use for treating pancreatic ducta...

Beam Gets Orphan Status for Genetic Disorder

[ Price : $8.95]

FDA grants Beam Therapeutics an orphan drug designation for BEAM-302, a liver-targeting lipid-nanoparticle that is designed to cor...

Former McKinsey Partner Sentenced for Purdue Work

[ Price : $8.95]

Former McKinsey & Company senior partner Martin Elling is sentenced to six months in federal prison, supervised release after inca...

Promising Trial Results for Wegovy Add-on: Veru

[ Price : $8.95]

Veru announces positive topline results from its Phase 2b QUALITY clinical trial that is evaluating enobosarm when added to semagl...

Mitsubishi Tanabe Resubmits NDA for Parkinsons Combo

[ Price : $8.95]

FDA accepts for review a Mitsubishi Tanabe Pharma America NDA resubmission for investigational ND0612, a continuous, subcutaneous ...

Zhejiang Huahai FDA-483 Released

[ Price : $8.95]

FDA releases the form FDA-483 with seven observations from a January inspection at Chinas Zhejiang Huahai Pharmaceuticals.

Multiple Issues at Germanys DRG Instruments

[ Price : $8.95]

FDA warns Marburg, Germany-based DRG Instruments that it is marketing diagnostic devices that do not have FDA approval and are bei...

House Democrats Want Answers on HHS Staff Cuts

[ Price : $8.95]

Complaining about a lack of information from the department, top Democrats on the House Energy and Commerce Committee ask HHS Secr...

FDA Publishes 2 Q-Submission Guidances

[ Price : $8.95]

FDA publishes two guidances relating to the CDRH/CBER Q-submission process.

GSK Plans for Antibiotic NDA in 2nd Half

[ Price : $8.95]

GSK plans to submit an NDA in the second half of the year after it and Spero Therapeutics announced that they will end their Phase...